SEC EDGARJUN 11 min read$ILMN

Meister Keith A. sold $3.2M of ILMN (indirect holdings)

Meister Keith A. sold 19,832 indirectly-held shares of ILLUMINA, INC. (ILMN) at $163.57 ($3.24M total) on 2026-05-29.

Original reporting

SEC EDGAR · Meister Keith A.

Published Jun 1, 2026, 10:04 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 1, 2026, 10:05 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ILMN

Neutral

medium confidence

Mentioned

$ILMN

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ILMNNeutralLow

Why it matters

The disclosure may slightly influence sentiment, but it does not introduce new guidance, contracts, litigation, or performance data.

Market read

Traders may monitor whether additional insider transactions follow, but the filing alone is unlikely to drive a sustained repricing.

What to watch

The article notes no pre-arranged 10b5-1 plan, which can increase interpretive weight, but the disclosure still lacks any stated reason for the sale or linkage to new information.

Relevance 6/10Novelty 6/10Timing: Filed June 1; sale dated May 29 (post-close disclosure window).

Background

This is an SEC Form 4 insider transaction: a director sold Illumina shares via open-market sale.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ILMNNeutralMedium confidence

Context

Illumina director Keith Meister sold 19,832 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely limited near-term impact; any effect should be small versus broader fundamentals.

Evidence & confidence

The filing is an ownership-change disclosure without accompanying operational/financial news; also the plan status (10b5-1 not used) can matter, but the article contains only the sale details.

Market effects

Sector

Minimal; single-company insider sale typically does not reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Director sales can be routine for diversification/tax and do not necessarily reflect a bearish view on Illumina’s prospects.

Key entities

issuer
Illumina, Inc.
Subject of the Form 4 insider sale disclosure.
insider
Keith A. Meister
Director who sold 19,832 shares on May 29, 2026.

Read at source ← All news

SEP 18

$ILMNHighAI 8/10

Illumina Q2FY26 Results: Revenue up 9.5% to $1.16 billion

Illumina reported Q2 2026 revenue of $1.16B, up 9.5% YoY, driven by NovaSeq X demand and clinical consumables growth. Non-GAAP EPS rose 10% to $1.31. The company raised full-year guidance, projecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40. Management cited strong instrument placements and cost management despite rising expenses. Illumina repurchased 0.9M shares and holds $1.17B in cash. The stock has returned 13.26% annually over 20 years, outperforming the market by 3.84%.

scanx.trade3 min

SEP 18

$ILMNHighAI 8/10

Illumina Reports Q2 2026 Results: Full Earnings Call Transcript - Illumina (NASDAQ:ILMN)

Illumina (ILMN) reported Q2 2026 revenue growth of 9.5% YoY and EPS growth of 10%, driven by strong demand for NovaSeq X. The company raised its 2026 guidance, expecting full-year organic revenue growth over 5% and mid-teens growth in clinical consumables. Strategic initiatives include expanding multi-omics capabilities and strengthening the BioInsight platform. Management emphasized cost management and confidence in long-term targets.

benzinga.com3 min

SEP 17

$ILMNMedAI 9/10

There's a biotech stock on Josh Brown's list that's ignoring the market noise and pushing higher

Illumina (ILMN) stock has risen 160% from its October 2025 low, defying broader market trends. The genomics company reported Q2 revenue of $1.16B, up 9.5% YoY, and raised full-year guidance. The stock is up 74.5% YTD and will be added to the S&P 500. Analysts note its strong technical performance and relative strength.

cnbc.com3 min

SEP 17

$BLSMHighAI 8/10

Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

rttnews.com3 min

SEP 16

$BELow

Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns?

Vanguard S&P 500 ETF (VOO) will add Bloom Energy (BE), Illumina (ILMN), and another company, while removing Molson Coors (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR). BE's product revenue surged 215% due to AI demand, and ILMN raised EPS guidance. The changes have minimal impact on VOO's returns, as the fund is heavily concentrated in megacap stocks.

yahoo.com3 min

SEP 15

$ILMNHigh

Illumina Stock Climbs As Analyst Upgrades Meet S&P 500 Boost

Illumina Inc. (ILMN) shares rose 7.15% on September 15, 2026, after UBS upgraded it to Buy with a $260 price target, and Argus raised its target to $235. The company's Q2 revenue was $1.16B, with EBITDA of $354M. Illumina is also being added to the S&P 500, effective September 21, 2026, which may drive further demand. The stock trades at a P/E ratio of 38 and P/S ratio of 6.9, reflecting its growth prospects. Analysts cite revenue reacceleration, margin expansion, and clinical demand as key driv

stockstotrade.com2 min